Related Experiment Video

Updated: Jul 12, 2026

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids
08:52

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids

Published on: November 22, 2021

[Interference therapy of laryngeal squamous cell carcinoma by p16beta and EGFR-antisense cDNA in signal transduction]

Jun-ming Xian1, Guang-yao Zhou, Chuan-yu Liang

  • 1Department of Otolaryngology, West China Hospital, Sichuan University, Chengdu 610041, China.

Sichuan Da Xue Xue Bao. Yi Xue Ban = Journal of Sichuan University. Medical Science Edition
|August 28, 2007
PubMed
Abstract

Insights

Introducing p16beta and EGFR-antisense cDNA into Hep-2 cells inhibits laryngeal cancer growth. This targeted therapy induces cell cycle arrest and promotes apoptosis, offering a potential strategy for treating laryngeal squamous cell carcinoma.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cell Biology

Background:

  • Laryngeal squamous cell carcinoma (LSCC) is a significant global health concern.
  • Understanding the molecular mechanisms driving LSCC progression is crucial for developing effective therapies.
  • Epidermal Growth Factor Receptor (EGFR) and p16beta are implicated in various cancers, including LSCC.

Purpose of the Study:

  • To investigate the in vitro effects of p16beta and EGFR-antisense cDNA on Hep-2 LSCC cells.
  • To evaluate the impact of these genetic modifications on signal transduction pathways, cell proliferation, and apoptosis.

Main Methods:

  • Hep-2 LSCC cells were transfected using recombinant adenovirus vectors carrying AdEasy-EGFR-antisense and AdEasy-p16beta.
  • Cell proliferation was assessed using MTT assays.
  • EGFR expression, cell cycle distribution, DNA content, and apoptosis were analyzed via Western blotting, flow cytometry, and transmission electron microscopy.

Main Results:

  • Transfection with Ad-p16beta or Ad-antisense EGFR significantly inhibited Hep-2 cell proliferation.
  • Both treatments led to increased apoptosis and a notable shift towards the G0/G1 phase of the cell cycle (over 77.7%).
  • Ad-antisense EGFR transfection resulted in decreased EGFR protein expression, while Ad-p16beta transfection led to p16beta protein overexpression.

Conclusions:

  • The introduction of Ad-p16beta and Ad-antisense EGFR into Hep-2 cells effectively upregulates p16beta and downregulates EGFR.
  • These genetic modifications induce G1-phase cell cycle arrest and promote apoptotic cell death in LSCC cells.
  • Both EGFR and p16beta play critical roles in the development, growth, and differentiation of human laryngeal cancer, suggesting their therapeutic potential.

More Related Videos

Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment07:29

Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment

Published on: April 22, 2019

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Inhibition of CDK Activity02:34

Inhibition of CDK Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.